Filtered By:
Cancer: Non-Small Cell Lung Cancer
Vaccination: Cancer Vaccines

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang, Dong Zhou, Yin Dai, Yanqi Li, Jiang Wu, Quanxing Liu, Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Conclusions MDSC are major players in the immunosuppressive scenario in cancer, thanks to their phenotype heterogeneity and critical interaction with several innate immune cells, thus representing a crucial target in oncology. Here we reviewed the interactions of MDSCs with NK cells. The contribution of key cytokines, chemokines and mediators active in this process have been discussed. We also described the contribution of MDSC on angiogenesis directly or indirectly through interactions with NK and immunosuppressive activities. A parallel of the cancer associated to the decidual counterpart of these cells is discussed, a...
Source: Frontiers in Immunology - April 17, 2019 Category: Allergy & Immunology Source Type: research

Abstract 5033: Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell
Conclusions: The findings obtained from the current study suggested that 5-FU and DTX may enhance the T cell-stimulating ability of DCs via down-regulation of PD-L1 and PD-L2 mediated by STAT3 inhibition, and that the combination therapy of DC-based cancer vaccine with these anti-cancer drugs may elicit better anti-tumor immune response than only vaccination. Citation Format: Masato Okamoto, Tomoyuki Tano, Hiroyuki Goda, Yohei Fujita, Koh-ichi Nakashiro, Hiroyuki Hamakawa. Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell. [abst...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Okamoto, M., Tano, T., Goda, H., Fujita, Y., Nakashiro, K.-i., Hamakawa, H. Tags: Immunology Source Type: research